The outcome with higher baseline risk should be selected for relative risk in clinical studies: A proposal for change to practice

Journal of Clinical Epidemiology

Volumn 67, Issue 4, 2014, Pages 364-367

  Furuya Kanamori, Luis ^a   Doi, Suhail A R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO; WARFARIN;

ARTICLE; ATTRIBUTABLE RISK; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; DISEASE COURSE; HUMAN; MATHEMATICAL PARAMETERS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 84896726392     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2013.10.010     Document Type: Note

References (10)

1. S. Doi Understanding evidence in health care: using clinical epidemiology 2012 Palgrave Macmillan South Yarra, Vic, Australia
2. B. Brumback, and A. Berg On effect-measure modification: relationships among changes in the relative risk, odds ratio, and risk difference Stat Med 27 2008 3453 3465
3. T.D. Cook Advanced statistics: up with odds ratios! A case for odds ratios when outcomes are common Acad Emerg Med 9 2002 1430 1434
4. S.D. Walter Choice of effect measure for epidemiological data J Clin Epidemiol 53 2000 931 939
5. P. Cummings The relative merits of risk ratios and odds ratios Arch Pediatr Adolesc Med 163 2009 438 445
6. S. Eckermann, M. Coory, and A.R. Willan Indirect comparison: relative risk fallacies and odds solution J Clin Epidemiol 62 2009 1031 1036
7. A.M. Glenny, D.G. Altman, F. Song, C. Sakarovitch, J.J. Deeks, and R. D'Amico et al. Indirect comparisons of competing interventions Health Technol Assess 9 2005 1 134
8. P. Duquette, B. Mishra, N. Delillio, J. Whitaker, B. Layton, and W.A. Sibley et al. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial Neurology 45 1995 1277 1285
9. J.C. Sinclair, and M.B. Bracken Clinically useful measures of effect in binary analyses of randomized trials J Clin Epidemiol 47 1994 881 889
10. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910